CA6823108759 - Common Stock
ONCOLYTICS BIOTECH INC
NASDAQ:ONCY (5/15/2024, 7:00:20 PM)
After market: 1.18 +0.02 (+1.72%)1.16
-0.02 (-1.69%)
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 29 full-time employees. The company went IPO on 2000-06-01. The firm is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7
P: 14036707377
CEO: Matthew C. Coffey
Employees: 29
Website: https://www.oncolyticsbiotech.com/
/PRNewswire/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood...
/CNW/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can...
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today...
/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...
ONCY stock results show that Oncolytics Biotech beat analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Oncolytics Biotech (NASDAQ:ONCY) just reported results for the first quarter of...
Here you can normally see the latest stock twits on ONCY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: